<p>Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - 獲取免費報告) 首席財務官 Sandip Kapadia 於 1 月 26 日星期一出售了 3,746 股 Harmony Biosciences 股票。股票以平均價格 $37.15 出售，總價值為 $139,163.90。出售完成後，首席財務官直接持有該公司 24,521 股股票，價值 $910,955.15。此次交易使其持股減少了 13.25%。該出售在向 SEC 提交的文件中披露，文件可通過此鏈接獲取。</p>
<p>Sandip Kapadia 最近還進行了以下交易：</p>
<ul>
<li>在 1 月 15 日星期四，Sandip Kapadia 出售了 20,961 股 Harmony Biosciences 股票。股票以平均價格 $35.92 出售，總價值為 $752,919.12。</li>
</ul>
<p>獲取 <strong>Harmony Biosciences</strong> 警報：</p>
<h2>Harmony Biosciences 股價下跌 2.2%</h2>
<p>在週三的交易中，NASDAQ HRMY 股價下跌 $0.84，跌至 $36.84。該股票的交易量為 503,087 股，而其平均交易量為 597,958 股。該公司的速動比率為 3.72，流動比率為 3.75，債務與股本比率為 0.18。該公司的市值為 21.2 億美元，市盈率為 11.58，市盈增長比率為 0.35，貝塔係數為 0.84。該公司 50 日移動平均價格為 $37.30，200 日移動平均價格為 $34.23。Harmony Biosciences Holdings, Inc. 的 12 個月低點為 $25.52，12 個月高點為 $40.87。</p>
<p>Harmony Biosciences (NASDAQ:HRMY - 獲取免費報告) 最近一次發佈季度財報是在 11 月 4 日星期二。該公司報告本季度每股收益為 $0.87，低於市場共識預期的 $0.92，差距為 ($0.05)。Harmony Biosciences 的淨利潤率為 22.50%，股本回報率為 24.88%。該公司在本季度的收入為 $239.46 百萬美元，而分析師預期為 $222.68 百萬美元。整體來看，股票研究分析師預測 Harmony Biosciences Holdings, Inc. 本年度每股收益將達到 2.43。</p>
<h2>對 Harmony Biosciences 的對沖基金看法</h2>
<p>一些機構投資者和對沖基金最近增加或減少了在 HRMY 的持股。Amundi 在第一季度將其在 Harmony Biosciences 的持股提高了 115.6%。Amundi 現在擁有 39,668 股該公司的股票，價值 $1,229,000，此前在上個季度購買了額外的 21,266 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度將其在 Harmony Biosciences 的持股增加了 4.5%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 現在擁有 22,651 股該公司的股票，價值 $752,000，此前在上個季度購買了額外的 984 股。Empowered Funds LLC 在第一季度收購了 Harmony Biosciences 的新股份，價值 $2,330,000。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 在第一季度將其在 Harmony Biosciences 的持股提高了 53.0%。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 現在擁有 95,389 股該公司的股票，價值 $3,166,000，此前在上個季度收購了額外的 33,058 股。最後，阿拉斯加州財政部在第二季度將其在 Harmony Biosciences 的持股提高了 8.1%。阿拉斯加州財政部現在擁有 22,897 股該公司的股票，價值 $722,000，此前在上個季度收購了額外的 1,724 股。86.23% 的股票由機構投資者和對沖基金持有。</p>
<h2>分析師設定新目標價</h2>
<p>一些研究分析師最近對 HRMY 股票發佈了報告。瑞穗證券在 12 月 1 日星期一將 Harmony Biosciences 的目標價從 $39.00 提高至 $46.00，並在報告中給予該公司 &#34;跑贏大盤&#34; 的評級。HC Wainwright 在 12 月 3 日星期三的研究報告中重申了對 Harmony Biosciences 股票的 &#34;買入&#34; 評級。Truist Financial 在 1 月 8 日星期四的研究報告中將 Harmony Biosciences 的目標價從 $48.00 降至 $45.00，併為該公司設定了 &#34;買入&#34; 評級。瑞銀集團在 10 月 15 日星期三的報告中將 Harmony Biosciences 股票的目標價從 $50.00 降至 $43.00，並對該股票設定了 &#34;買入&#34; 評級。最後，華爾街 Zen 在 12 月 13 日星期六的研究報告中將 Harmony Biosciences 股票的評級從 &#34;持有&#34; 上調至 &#34;買入&#34;。兩位研究分析師對該股票給予了強烈買入評級，七位給予了買入評級，兩位給予了持有評級。根據 MarketBeat.com 的數據，該公司的平均評級為 &#34;買入&#34;，平均目標價為 $45.25。</p>
<p><strong>查看我們最新的 Harmony Biosciences 股票報告</strong></p>
<h2>Harmony Biosciences 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Harmony Biosciences Holdings, Inc 是一家商業階段的生物製藥公司，專注於開發和提供針對罕見神經和內分泌疾病患者的治療方案。公司成立於 2017 年，總部位於賓夕法尼亞州普利茅斯會議，Harmony Biosciences 於 2020 年上市，並在納斯達克以 HRMY 的股票代碼交易。公司的使命是識別和推進能夠滿足現有治療方案無法滿足的患者羣體的關鍵未滿足需求的藥物。</p>
<p>該公司的旗艦產品是 WAKIX（pitolisant），這是美國批准的首個也是唯一的組胺 H3 受體拮抗劑/反向激動劑。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票比 Harmony Biosciences 更好</li>
<li>您的簽名缺失 - 請在為時已晚之前採取行動</li>
<li>在星期一上午 9:30 購買此股票！</li>
<li>特朗普剛剛簽署了它</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>請勿刪除，立即閲讀</li>
</ul>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 $1,000 在 Harmony Biosciences 嗎？</h2>
<p>在你考慮 Harmony Biosciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Harmony Biosciences 並不在名單上。</p>
<p>雖然 Harmony Biosciences 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

HRMY

<p>Harmony Biosciences 的首席財務官 Sandip Kapadia 出售了 3,746 股，價格為每股 37.15 美元，總計 139,163.90 美元，減少了 13.25% 的持股，剩餘 24,521 股，價值 910,955.15 美元。此交易已向美國證券交易委員會（SEC）披露。最近，他還以平均價格 35.92 美元出售了 20,961 股。該股票目前交易價格為 36.84 美元，下跌 2.2%。Harmony 報告的季度每股收益（EPS）為 0.87 美元，未達到預期，收入為 2.3946 億美元。分析師們設定了新的目標價格，其中瑞穗證券將其目標價上調至 46.00 美元，並維持 “跑贏大盤” 的評級</p>

<p>Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) CFO Sandip Kapadia sold 3,746 shares of Harmony Biosciences stock in a transaction on Monday, January 26th. The shares were sold at an average price of $37.15, for a total value of $139,163.90. Following the completion of the sale, the chief financial officer directly owned 24,521 shares of the company's stock, valued at $910,955.15. The trade was a 13.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.</p>
<div class="lb-trans"><p>Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - 獲取免費報告) 首席財務官 Sandip Kapadia 於 1 月 26 日星期一出售了 3,746 股 Harmony Biosciences 股票。股票以平均價格 $37.15 出售，總價值為 $139,163.90。出售完成後，首席財務官直接持有該公司 24,521 股股票，價值 $910,955.15。此次交易使其持股減少了 13.25%。該出售在向 SEC 提交的文件中披露，文件可通過此鏈接獲取。</p>
</div><p>Sandip Kapadia also recently made the following trade(s):</p>
<div class="lb-trans"><p>Sandip Kapadia 最近還進行了以下交易：</p>
</div><ul>
<li>On Thursday, January 15th, Sandip Kapadia sold 20,961 shares of Harmony Biosciences stock. The shares were sold at an average price of $35.92, for a total value of $752,919.12.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 1 月 15 日星期四，Sandip Kapadia 出售了 20,961 股 Harmony Biosciences 股票。股票以平均價格 $35.92 出售，總價值為 $752,919.12。</li>
</ul>
</div><p>Get <strong>Harmony Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Harmony Biosciences</strong> 警報：</p>
</div><h2>Harmony Biosciences Trading Down 2.2%</h2>
<div class="lb-trans"><h2>Harmony Biosciences 股價下跌 2.2%</h2>
</div><p>NASDAQ HRMY traded down $0.84 during trading on Wednesday, hitting $36.84. The stock had a trading volume of 503,087 shares, compared to its average volume of 597,958. The company has a quick ratio of 3.72, a current ratio of 3.75 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $2.12 billion, a PE ratio of 11.58, a PEG ratio of 0.35 and a beta of 0.84. The firm has a 50 day moving average price of $37.30 and a 200 day moving average price of $34.23. Harmony Biosciences Holdings, Inc. has a twelve month low of $25.52 and a twelve month high of $40.87.</p>
<div class="lb-trans"><p>在週三的交易中，NASDAQ HRMY 股價下跌 $0.84，跌至 $36.84。該股票的交易量為 503,087 股，而其平均交易量為 597,958 股。該公司的速動比率為 3.72，流動比率為 3.75，債務與股本比率為 0.18。該公司的市值為 21.2 億美元，市盈率為 11.58，市盈增長比率為 0.35，貝塔係數為 0.84。該公司 50 日移動平均價格為 $37.30，200 日移動平均價格為 $34.23。Harmony Biosciences Holdings, Inc. 的 12 個月低點為 $25.52，12 個月高點為 $40.87。</p>
</div><p>Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.05). Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. The business had revenue of $239.46 million during the quarter, compared to analysts' expectations of $222.68 million. As a group, equities research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.</p>
<div class="lb-trans"><p>Harmony Biosciences (NASDAQ:HRMY - 獲取免費報告) 最近一次發佈季度財報是在 11 月 4 日星期二。該公司報告本季度每股收益為 $0.87，低於市場共識預期的 $0.92，差距為 ($0.05)。Harmony Biosciences 的淨利潤率為 22.50%，股本回報率為 24.88%。該公司在本季度的收入為 $239.46 百萬美元，而分析師預期為 $222.68 百萬美元。整體來看，股票研究分析師預測 Harmony Biosciences Holdings, Inc. 本年度每股收益將達到 2.43。</p>
</div><h2>Hedge Funds Weigh In On Harmony Biosciences</h2>
<div class="lb-trans"><h2>對 Harmony Biosciences 的對沖基金看法</h2>
</div><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in HRMY. Amundi raised its holdings in Harmony Biosciences by 115.6% during the first quarter. Amundi now owns 39,668 shares of the company's stock worth $1,229,000 after purchasing an additional 21,266 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Harmony Biosciences by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company's stock valued at $752,000 after buying an additional 984 shares during the last quarter. Empowered Funds LLC acquired a new stake in Harmony Biosciences during the 1st quarter worth $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Harmony Biosciences by 53.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company's stock worth $3,166,000 after acquiring an additional 33,058 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its position in Harmony Biosciences by 8.1% in the second quarter. State of Alaska Department of Revenue now owns 22,897 shares of the company's stock valued at $722,000 after acquiring an additional 1,724 shares during the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近增加或減少了在 HRMY 的持股。Amundi 在第一季度將其在 Harmony Biosciences 的持股提高了 115.6%。Amundi 現在擁有 39,668 股該公司的股票，價值 $1,229,000，此前在上個季度購買了額外的 21,266 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度將其在 Harmony Biosciences 的持股增加了 4.5%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 現在擁有 22,651 股該公司的股票，價值 $752,000，此前在上個季度購買了額外的 984 股。Empowered Funds LLC 在第一季度收購了 Harmony Biosciences 的新股份，價值 $2,330,000。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 在第一季度將其在 Harmony Biosciences 的持股提高了 53.0%。UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC 現在擁有 95,389 股該公司的股票，價值 $3,166,000，此前在上個季度收購了額外的 33,058 股。最後，阿拉斯加州財政部在第二季度將其在 Harmony Biosciences 的持股提高了 8.1%。阿拉斯加州財政部現在擁有 22,897 股該公司的股票，價值 $722,000，此前在上個季度收購了額外的 1,724 股。86.23% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>A number of research analysts recently issued reports on HRMY shares. Mizuho lifted their target price on Harmony Biosciences from $39.00 to $46.00 and gave the company an &#34;outperform&#34; rating in a report on Monday, December 1st. HC Wainwright reiterated a &#34;buy&#34; rating on shares of Harmony Biosciences in a research note on Wednesday, December 3rd. Truist Financial lowered their price objective on Harmony Biosciences from $48.00 to $45.00 and set a &#34;buy&#34; rating for the company in a research report on Thursday, January 8th. UBS Group reduced their target price on shares of Harmony Biosciences from $50.00 to $43.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, October 15th. Finally, Wall Street Zen upgraded shares of Harmony Biosciences from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, December 13th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of &#34;Buy&#34; and an average target price of $45.25.</p>
<div class="lb-trans"><p>一些研究分析師最近對 HRMY 股票發佈了報告。瑞穗證券在 12 月 1 日星期一將 Harmony Biosciences 的目標價從 $39.00 提高至 $46.00，並在報告中給予該公司 &#34;跑贏大盤&#34; 的評級。HC Wainwright 在 12 月 3 日星期三的研究報告中重申了對 Harmony Biosciences 股票的 &#34;買入&#34; 評級。Truist Financial 在 1 月 8 日星期四的研究報告中將 Harmony Biosciences 的目標價從 $48.00 降至 $45.00，併為該公司設定了 &#34;買入&#34; 評級。瑞銀集團在 10 月 15 日星期三的報告中將 Harmony Biosciences 股票的目標價從 $50.00 降至 $43.00，並對該股票設定了 &#34;買入&#34; 評級。最後，華爾街 Zen 在 12 月 13 日星期六的研究報告中將 Harmony Biosciences 股票的評級從 &#34;持有&#34; 上調至 &#34;買入&#34;。兩位研究分析師對該股票給予了強烈買入評級，七位給予了買入評級，兩位給予了持有評級。根據 MarketBeat.com 的數據，該公司的平均評級為 &#34;買入&#34;，平均目標價為 $45.25。</p>
</div><p><strong>View Our Latest Stock Report on Harmony Biosciences</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Harmony Biosciences 股票報告</strong></p>
</div><h2>Harmony Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Harmony Biosciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company's mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.</p>
<div class="lb-trans"><p>Harmony Biosciences Holdings, Inc 是一家商業階段的生物製藥公司，專注於開發和提供針對罕見神經和內分泌疾病患者的治療方案。公司成立於 2017 年，總部位於賓夕法尼亞州普利茅斯會議，Harmony Biosciences 於 2020 年上市，並在納斯達克以 HRMY 的股票代碼交易。公司的使命是識別和推進能夠滿足現有治療方案無法滿足的患者羣體的關鍵未滿足需求的藥物。</p>
</div><p>The company's flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.</p>
<div class="lb-trans"><p>該公司的旗艦產品是 WAKIX（pitolisant），這是美國批准的首個也是唯一的組胺 H3 受體拮抗劑/反向激動劑。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than Harmony Biosciences</li>
<li>Your Signature Is Missing – Act Before It’s Too Late</li>
<li>Buy This Stock at 9:30 AM on MONDAY!</li>
<li>Trump just signed it</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>Do not delete, read immediately</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Harmony Biosciences 更好</li>
<li>您的簽名缺失 - 請在為時已晚之前採取行動</li>
<li>在星期一上午 9:30 購買此股票！</li>
<li>特朗普剛剛簽署了它</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>請勿刪除，立即閲讀</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Harmony Biosciences Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 $1,000 在 Harmony Biosciences 嗎？</h2>
</div><p>Before you consider Harmony Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Harmony Biosciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Harmony Biosciences 並不在名單上。</p>
</div><p>While Harmony Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Harmony Biosciences 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Sandip Kapadia 出售了 Harmony Biosciences（NASDAQ:HRMY）股票中的 3,746 股